RxSight, Inc. to Report Third Quarter 2025 Financial Results on November 5, 2025

Rhea-AI Summary

RxSight (Nasdaq: RXST) will report third quarter 2025 financial results after market close on Wednesday, November 5, 2025.

Management will discuss results on a conference call at 1:30 p.m. PT / 4:30 p.m. ET. To join by phone dial (800) 715-9871 or (646) 307-1963 and enter conference code 6619966.

The call will be broadcast in listen-only mode and archived on the company investor relations site at https://investors.rxsight.com/.

News Market Reaction – RXST

-1.17%

-1.17% Session close to close

In the Oct 23 session, RXST declined 1.17%, reflecting a mild negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

ALISO VIEJO, Calif., Oct. 22, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: RXST) – RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery, will report financial results for the third quarter of 2025 after the market close on Wednesday, November 5, 2025. The company’s management will discuss the results during a conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.

To participate in the conference call, please dial (800) 715-9871 or (646) 307-1963, and enter the conference code: 6619966. The call will also be broadcast live in listen-only mode via a link on the company’s investor relations website at https://investors.rxsight.com/. An archived recording of the call will be available through the same link shortly after its completion.

About RxSight, Inc.

RxSight, Inc. is an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery. The RxSight® Light Adjustable Lens system, comprised of the RxSight Light Adjustable Lens® (LAL®/LAL+®, collectively the “LAL”), RxSight Light Delivery Device (LDD™) and accessories, is the first and only commercially available intraocular lens (IOL) technology that can be adjusted after surgery, enabling doctors to customize and deliver high-quality vision to patients after cataract surgery. Additional information about RxSight can be found at www.rxsight.com.

Company Contact:
Shelley B. Thunen
Chief Financial Officer
sthunen@rxsight.com

Investor Relations Contact:
Oliver Moravcevic
VP, Investor Relations
omoravcevic@rxsight.com

FAQ

When will RxSight (RXST) report third quarter 2025 results?

RxSight will report third quarter 2025 results after market close on Wednesday, November 5, 2025.

What time is the RxSight (RXST) Q3 2025 earnings conference call?

The conference call begins at 1:30 p.m. PT / 4:30 p.m. ET on November 5, 2025.

How can I dial into the RxSight (RXST) Q3 2025 conference call?

Dial (800) 715-9871 or (646) 307-1963 and enter conference code 6619966.

Will RxSight (RXST) provide a webcast of the November 5, 2025 call?

Yes. A listen-only live webcast and an archived recording will be available at https://investors.rxsight.com/.

Where will the archived recording of the RxSight (RXST) Q3 2025 call be posted?

The archived recording will be posted on the company's investor relations site at https://investors.rxsight.com/ shortly after the call.

Is the RxSight (RXST) November 5, 2025 call open to investors by phone?

Yes. Investors can join by phone using the provided dial-in numbers and conference code 6619966.